GGrantIndex
← Search

CANARYPOX ALVAC HIV VACCINES IN HIV 1 UNINFECTED ADULT VOLUNTEERS

$592M01FY2000RRNIH

Vanderbilt University, Nashville TN

Investigators

Linked publications & trials

Abstract

This study will compare the safety and immunogenicity of three different ALVAC-HIV recombinant canarypox vector vaccines (vCP205 versus vCP1433 versus vCP1452), each given twice, followed by immunization twice with the same ALVAC-HIV recombinant and subunit HIV-1 gp 160 MN/LAI-2 vaccine in polyphosphazene adjuvant in each arm of the study.

View original record on NIH RePORTER →